Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy

Cancer Cell

Volumn 27, Issue 6, 2015, Pages 852-863

  Han, Bingshe ^a,d   Park, Dongkyoo ^a   Li, Rui ^a   Xie, Maohua ^a   Owonikoko, Taofeek K ^a   Zhang, Guojing ^a   Sica, Gabriel L ^a   Ding, Chunyong ^b   Zhou, Jia ^b   Magis, Andrew T ^c   Chen, Zhuo G ^a   Shin, Dong M ^a   Ramalingam, Suresh S ^a   Khuri, Fadlo R ^a   Curran, Walter J ^a   Deng, Xingming ^a  

^a EMORY UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d SHANGHAI OCEAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BDA 366; BECLIN 1; BH3 PROTEIN; BH4 PROTEIN; CASPASE 3; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEAR RECEPTOR NUR77; PEPTIDES AND PROTEINS; PROTEIN BAX; PROTEIN BCL 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VENETOCLAX; BCL2 PROTEIN, HUMAN; BCL2 PROTEIN, MOUSE; MOLECULAR LIBRARY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL KILLING; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG DNA BINDING; DRUG DOSE INCREASE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; MALE; METABOLISM; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930573524     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.04.010     Document Type: Article

References (57)

1. Aguirre D., Boya P., Bellet D., Faivre S., Troalen F., Benard J., Saulnier P., Hopkins-Donaldson S., Zangemeister-Wittke U., Kroemer G., Raymond E. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004, 9:797-805.
2. Bartel C., Bytzek A.K., Scaffidi-Domianello Y.Y., Grabmann G., Jakupec M.A., Hartinger C.G., Galanski M., Keppler B.K. Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. J.Biol. Inorg. Chem. 2012, 17:465-474.
3. Besse B., Leighl N., Bennouna J., Papadimitrakopoulou V.A., Blais N., Traynor A.M., Soria J.C., Gogov S., Miller N., Jehl V., Johnson B.E. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann. Oncol. 2014, 25:409-415.
4. Bruncko M., Oost T.K., Belli B.A., Ding H., Joseph M.K., Kunzer A., Martineau D., McClellan W.J., Mitten M., Ng S.C., et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J.Med. Chem. 2007, 50:641-662.
5. Castelli M., Reiners J.J., Kessel D. A mechanism for the proapoptotic activity of ursodeoxycholic acid: effects on Bcl-2 conformation. Cell Death Differ. 2004, 11:906-914.
6. Cheng E.H., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., Ueno K., Hardwick J.M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997, 278:1966-1968.
7. Chonghaile T.N., Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008, 27(Suppl 1):S149-S157.
8. de Moissac D., Zheng H., Kirshenbaum L.A. Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J.Biol. Chem. 1999, 274:29505-29509.
9. Deng X., Xiao L., Lang W., Gao F., Ruvolo P., May W.S. Novel role for JNK as a stress-activated Bcl2 kinase. J.Biol. Chem. 2001, 276:23681-23688.
10. Deng X., Gao F., Flagg T., Anderson J., May W.S. Bcl2's flexible loop domain regulates p53 binding and survival. Mol. Cell. Biol. 2006, 26:4421-4434.
11. Deng X., Gao F., May W.S. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 2009, 113:422-428.
12. Enyedy I.J., Ling Y., Nacro K., Tomita Y., Wu X., Cao Y., Guo R., Li B., Zhu X., Huang Y., et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J.Med. Chem. 2001, 44:4313-4324.
13. Gavathiotis E., Reyna D.E., Bellairs J.A., Leshchiner E.S., Walensky L.D. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 2012, 8:639-645.
14. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M., Lenox J., Cerveny C.G., Kissler K.M., Bernhardt S.X., Kopcha A.K., Zabinski R.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10:7063-7070.
15. Hao J., Madigan M.C., Khatri A., Power C.A., Hung T.T., Beretov J., Chang L., Xiao W., Cozzi P.J., Graham P.H., et al. Invitro and invivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS ONE 2012, 7:e40716.
16. Hirotani M., Zhang Y., Fujita N., Naito M., Tsuruo T. NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis. J.Biol. Chem. 1999, 274:20415-20420.
17. Hou Y., Gao F., Wang Q., Zhao J., Flagg T., Zhang Y., Deng X. Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex. J.Biol. Chem. 2007, 282:9279-9287.
18. Hsu Y.T., Youle R.J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J.Biol. Chem. 1998, 273:10777-10783.
19. Hsu Y.T., Wolter K.G., Youle R.J. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. USA 1997, 94:3668-3672.
20. Hunter J.J., Bond B.L., Parslow T.G. Functional dissection of the human Bc12 protein: sequence requirements for inhibition of apoptosis. Mol. Cell. Biol. 1996, 16:877-883.
21. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
22. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
23. Kelekar A., Thompson C.B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8:324-330.
24. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
25. Lassus P., Rodriguez J., Lazebnik Y. Confirming specificity of RNAi in mammalian cells. Sci. STKE 2002, 2002:pl13.
26. Legrier M.E., Yang C.P., Yan H.G., Lopez-Barcons L., Keller S.M., Pérez-Soler R., Horwitz S.B., McDaid H.M. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007, 67:11300-11308.
27. Li R., Hu Z., Sun S.Y., Chen Z.G., Owonikoko T.K., Sica G.L., Ramalingam S.S., Curran W.J., Khuri F.R., Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 2013, 12:2200-2212.
28. Liang C., Feng P., Ku B., Dotan I., Canaani D., Oh B.H., Jung J.U. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat. Cell Biol. 2006, 8:688-699.
29. Lim L.Y., Vidnovic N., Ellisen L.W., Leong C.O. Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer 2009, 101:1606-1612.
30. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., Dawson M.I., Reed J.C., Zhang X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116:527-540.
31. Liu Y., Sun S.Y., Owonikoko T.K., Sica G.L., Curran W.J., Khuri F.R., Deng X. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol. Cancer Ther. 2012, 11:45-56.
32. Maiuri M.C., Le Toumelin G., Criollo A., Rain J.C., Gautier F., Juin P., Tasdemir E., Pierron G., Troulinaki K., Tavernarakis N., et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007, 26:2527-2539.
33. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10:594-601.
34. Monaco G., Decrock E., Akl H., Ponsaerts R., Vervliet T., Luyten T., De Maeyer M., Missiaen L., Distelhorst C.W., De Smedt H., et al. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death Differ. 2012, 19:295-309.
35. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
36. Owonikoko T.K., Ramalingam S.S., Miller D.L., Force S.D., Sica G.L., Mendel J., Chen Z., Rogatko A., Tighiouart M., Harvey R.D., et al. A translational, pharmacodynamic and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer. Clin. Cancer Res. 2015, 21:1859-1868.
37. Park D., Magis A.T., Li R., Owonikoko T.K., Sica G.L., Sun S.Y., Ramalingam S.S., Khuri F.R., Curran W.J., Deng X. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer Res. 2013, 73:5485-5496.
38. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
39. Ramalingam S.S., Owonikoko T.K., Behera M., Subramanian J., Saba N.F., Kono S.A., Gal A.A., Sica G., Harvey R.D., Chen Z., et al. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J.Thorac. Oncol. 2013, 8:369-372.
40. Reed J.C., Zha H., Aime-Sempe C., Takayama S., Wang H.G. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv. Exp. Med. Biol. 1996, 406:99-112.
41. Rong Y.P., Aromolaran A.S., Bultynck G., Zhong F., Li X., McColl K., Matsuyama S., Herlitze S., Roderick H.L., Bootman M.D., et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol. Cell 2008, 31:255-265.
42. Rong Y.P., Bultynck G., Aromolaran A.S., Zhong F., Parys J.B., De Smedt H., Mignery G.A., Roderick H.L., Bootman M.D., Distelhorst C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl. Acad. Sci. USA 2009, 106:14397-14402.
43. Sartorius U.A., Krammer P.H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int. J. Cancer 2002, 97:584-592.
44. Schoenwaelder S.M., Jarman K.E., Gardiner E.E., Hua M., Qiao J., White M.J., Josefsson E.C., Alwis I., Ono A., Willcox A., et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011, 118:1663-1674.
45. Song L., Coppola D., Livingston S., Cress D., Haura E.B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 2005, 4:267-276.
46. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
47. Tarhini A., Kotsakis A., Gooding W., Shuai Y., Petro D., Friedland D., Belani C.P., Dacic S., Argiris A. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin. Cancer Res. 2010, 16:5900-5907.
48. Trisciuoglio D., De Luca T., Desideri M., Passeri D., Gabellini C., Scarpino S., Liang C., Orlandi A., Del Bufalo D. Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth. Neoplasia 2013, 15:315-327.
49. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
50. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
51. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., Croce C.M., Alnemri E.S., Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 2000, 97:7124-7129.
52. Wang Q., Gao F., May W.S., Zhang Y., Flagg T., Deng X. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol. Cell 2008, 29:488-498.
53. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
54. Xie M., Yen Y., Owonikoko T.K., Ramalingam S.S., Khuri F.R., Curran W.J., Doetsch P.W., Deng X. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase. Cancer Res. 2014, 74:212-223.
55. Yin X.M., Oltvai Z.N., Korsmeyer S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369:321-323.
56. Zhang H., Nimmer P., Rosenberg S.H., Ng S.C., Joseph M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal. Biochem. 2002, 307:70-75.
57. +-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood 2011, 117:2924-2934.